DE69018990D1 - Stabile interleukine enthaltende impfstoffzusammensetzungen. - Google Patents

Stabile interleukine enthaltende impfstoffzusammensetzungen.

Info

Publication number
DE69018990D1
DE69018990D1 DE69018990T DE69018990T DE69018990D1 DE 69018990 D1 DE69018990 D1 DE 69018990D1 DE 69018990 T DE69018990 T DE 69018990T DE 69018990 T DE69018990 T DE 69018990T DE 69018990 D1 DE69018990 D1 DE 69018990D1
Authority
DE
Germany
Prior art keywords
vaccine compositions
interleukine
stable
compositions containing
interleukin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69018990T
Other languages
English (en)
Other versions
DE69018990T2 (de
Inventor
Subramonia Pillai
Garvin Bixler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
Praxis Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Biologics Inc filed Critical Praxis Biologics Inc
Application granted granted Critical
Publication of DE69018990D1 publication Critical patent/DE69018990D1/de
Publication of DE69018990T2 publication Critical patent/DE69018990T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69018990T 1989-07-14 1990-07-16 Stabile interleukine enthaltende impfstoffzusammensetzungen. Expired - Fee Related DE69018990T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37974289A 1989-07-14 1989-07-14
PCT/US1990/003982 WO1991001143A1 (en) 1989-07-14 1990-07-16 Stable vaccine compositions containing interleukins

Publications (2)

Publication Number Publication Date
DE69018990D1 true DE69018990D1 (de) 1995-06-01
DE69018990T2 DE69018990T2 (de) 1995-12-14

Family

ID=23498494

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69018990T Expired - Fee Related DE69018990T2 (de) 1989-07-14 1990-07-16 Stabile interleukine enthaltende impfstoffzusammensetzungen.

Country Status (12)

Country Link
EP (1) EP0482076B1 (de)
JP (2) JP3485184B2 (de)
KR (1) KR0177179B1 (de)
AT (1) ATE121629T1 (de)
AU (1) AU648509B2 (de)
CA (1) CA2063587C (de)
DE (1) DE69018990T2 (de)
DK (1) DK0482076T3 (de)
ES (1) ES2075900T3 (de)
FI (1) FI104233B1 (de)
NO (1) NO301577B1 (de)
WO (1) WO1991001143A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
CA2071478A1 (en) * 1989-10-27 1991-04-28 Jeffery A. Bluestone Methods and compositions for promoting immunopotentiation
GR1000881B (el) * 1990-08-06 1993-03-16 Praxis Biolog Inc Σταθερες συνθεσεις εμβολιου που περιεχουν ιντερλευκινες.
ATE129900T1 (de) * 1990-12-19 1995-11-15 Schering Corp Anwendung von il-4 zur steigerung der immunantwort auf immunogene in impfstoffen.
WO1992020370A1 (en) * 1991-05-13 1992-11-26 Regents Of The University Of California Liposomal polysaccharide vaccines
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
DE69310182T2 (de) * 1992-08-10 1997-12-04 Us Health Interleukin-4 stimulierter t-lymphozyten-zelltod
ZA936095B (en) * 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
WO1996007102A1 (en) * 1994-09-01 1996-03-07 Wisconsin Alumni Research Foundation Therapeutic remodeling in aids
US6509313B1 (en) * 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
ES2262181T3 (es) * 1996-05-31 2006-11-16 National University Of Ireland, Maynooth Il-12 como adyuvante en la vacuna contra la especie bordetella pertussis.
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
US6270758B1 (en) 1998-10-08 2001-08-07 Duke University Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
US6027731A (en) * 1998-11-17 2000-02-22 Wisconsin Alumni Research Foundation Pertussis toxin induced lymphocytosis
IT1302534B1 (it) 1998-12-21 2000-09-05 Fidia Advanced Biopolymers Srl Composizioni iniettabili, biocompatibili e biodegradabili comprendentialmeno un derivato dell'acido ialuronico, cellule condrogeniche, per
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001039803A2 (en) 1999-12-03 2001-06-07 Celltech Chiroscience Ltd. Interleukin-1 muteins useful as vaccine adjuvants
CA2614640A1 (en) 2005-07-11 2007-01-18 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
WO2007039584A1 (en) * 2005-09-30 2007-04-12 Lipoxen Technologies Limited Multivalent liposomal vaccine compositions comprising polysaccharide antigens and a protein adjuvant
SG177907A1 (en) 2006-06-14 2012-02-28 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
EP2129394B1 (de) * 2007-03-09 2012-06-20 Merck Sharp & Dohme Corp. Impfstoffzusammensetzung gegen papillomavirus
EP2925297B1 (de) * 2012-11-02 2017-06-21 CyTuVax Zusammensetzung enthaltend zytokin makroaggregate
JOP20190242A1 (ar) * 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
WO2020102728A1 (en) 2018-11-16 2020-05-22 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
JP2023512456A (ja) 2020-01-13 2023-03-27 ネオイミューンテック， インコーポレイテッド Ｉｌ－７タンパク質と二重特異性抗体の組み合わせで腫瘍を治療する方法
US20230210952A1 (en) 2020-02-05 2023-07-06 Washington University Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
EP4232070A1 (de) 2020-10-26 2023-08-30 NeoImmuneTech, Inc. Verfahren zur induktion von stammzellenmobilisierung
EP4236989A1 (de) 2020-11-02 2023-09-06 NeoImmuneTech, Inc. Verwendung von interleukin-7 zur behandlung des coronavirus
EP4240408A1 (de) 2020-11-05 2023-09-13 Neoimmunetech, Inc. Verfahren zur behandlung eines tumors mit einer kombination aus einem il-7-protein und einem nukleotidimpfstoff
WO2023130081A1 (en) 2021-12-30 2023-07-06 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
WO2024102722A1 (en) 2022-11-07 2024-05-16 Neoimmunetech, Inc. Methods of treating a tumor with an unmethylated mgmt promoter

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
DE3818054C2 (de) * 1988-05-27 1994-02-17 Biotest Pharma Gmbh Verwendung einer Kombination aus einem Antigen bzw. einer Vakzine und humanem Interleukin zur Behandlung der Non-Responsiveness gegenüber immunologischen Defektzuständen
JPH0236129A (ja) * 1988-07-22 1990-02-06 Ajinomoto Co Inc ワクチン効果増強剤

Also Published As

Publication number Publication date
KR0177179B1 (ko) 1999-03-20
NO920161L (no) 1992-03-05
FI920132A0 (fi) 1992-01-13
DK0482076T3 (da) 1995-07-17
FI104233B (fi) 1999-12-15
CA2063587C (en) 2005-08-30
NO920161D0 (no) 1992-01-13
DE69018990T2 (de) 1995-12-14
JP3485184B2 (ja) 2004-01-13
JP2004002463A (ja) 2004-01-08
KR920703103A (ko) 1992-12-17
JPH04506663A (ja) 1992-11-19
AU6050090A (en) 1991-02-22
WO1991001143A1 (en) 1991-02-07
EP0482076A1 (de) 1992-04-29
CA2063587A1 (en) 1991-01-15
EP0482076B1 (de) 1995-04-26
ATE121629T1 (de) 1995-05-15
AU648509B2 (en) 1994-04-28
NO301577B1 (no) 1997-11-17
ES2075900T3 (es) 1995-10-16
FI104233B1 (fi) 1999-12-15

Similar Documents

Publication Publication Date Title
DE69018990D1 (de) Stabile interleukine enthaltende impfstoffzusammensetzungen.
FI945483A (fi) Hepatiitti B - pinta-antigeenejä ja muita antigeenejä sisältäviä yhdistelmärokotteita
GB2210557B (en) Vaccine containing tumor antigens and refined detoxified endotoxin as an adjuvant.
MX9203294A (es) Factor de estimulacion de aniquilador natural.
IT8322155A0 (it) Procedimento per immobilizzare materie biologiche e composto di materie biologiche adsorbite in vermiculite.
ES2092306T3 (es) Adyuvante para vacunas.
MX9803290A (es) Composiciones de la vacuna influenza.
GB8403921D0 (en) Preparation of lyophilized adsorbed polyvalent vaccines
ATE61937T1 (de) Antigenische zubereitungen und isolierung von solchen zubereitungen.
SE8404707L (sv) Komposition innehallande pyridinlosligt extrakt och raffinerat detoxifierat endotoxin samt anvendning derav
PT90710A (pt) Processo para a preparacao de silica para composicoes dentifricas compativel designadamente com zinco
AU1813701A (en) Interleukin-1 muteins useful as vaccine adjuvants
ATE275421T1 (de) Interleukin-12 und herpes simplex virusantigen enthaltende impfstoffe
DE3485638D1 (de) Zubereitung von nitroestern fuer die koronartherapie.
DK0884329T3 (da) Anti-idiotypisk antistof, som inducerer en immunreaktion mod et glycosphingolipid, samt anvendelse deraf
DE60132427D1 (de) Gebrauch von opri lipoprotein aus pseudomonas als th1 induzierendes natürliches adjuvans für heterologe antigene
DK504389A (da) Adjuveret antigenoploesning, dens fremstilling samt zink- eller jernhydroxidgel til anvendelse derved
DK0538341T3 (da) EHV-4-gycoproteinvaccine.
ES2088431T3 (es) Preparacion biologica y su utilizacion.
JPS55106261A (en) Composition made of dispersed body of colloid silica and colloid titania
ES2056378T3 (es) Procedimiento de extraccion.
GB2227936A (en) Vaccine against brucella abortus
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
IT1177974B (it) Composizione comprendente endotossina detossificata raffinata
GR1000881B (el) Σταθερες συνθεσεις εμβολιου που περιεχουν ιντερλευκινες.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: AMERICAN CYANAMID CO., PORTLAND, ME., US

8327 Change in the person/name/address of the patent owner

Owner name: WYETH HOLDINGS CORP., MADISON, N.J., US

8339 Ceased/non-payment of the annual fee